Wall Street brokerages forecast that AbbVie Inc. (NYSE:ABBV) will report earnings of $1.38 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for AbbVie’s earnings, with the highest EPS estimate coming in at $1.40 and the lowest estimate coming in at $1.36. AbbVie reported earnings of $1.21 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 14%. The firm is scheduled to announce its next quarterly earnings report on Friday, October 27th.

According to Zacks, analysts expect that AbbVie will report full-year earnings of $5.52 per share for the current financial year, with EPS estimates ranging from $5.47 to $5.57. For the next year, analysts anticipate that the company will report earnings of $6.57 per share, with EPS estimates ranging from $6.32 to $7.07. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow AbbVie.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 154.76%. The company had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 7.6% on a year-over-year basis.

Several research analysts recently commented on ABBV shares. Vetr downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $71.84 price objective for the company. in a report on Monday, May 15th. Jefferies Group LLC reaffirmed a “buy” rating on shares of AbbVie in a report on Friday, May 26th. Societe Generale raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $85.00 price objective on shares of AbbVie in a report on Thursday, August 3rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $75.35.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/08/analysts-anticipate-abbvie-inc-abbv-will-post-earnings-of-1-38-per-share.html.

AbbVie (ABBV) traded up 0.35% during midday trading on Thursday, hitting $71.47. 4,398,003 shares of the stock were exchanged. AbbVie has a 1-year low of $55.06 and a 1-year high of $75.04. The firm’s 50-day moving average price is $72.12 and its 200 day moving average price is $66.41. The firm has a market capitalization of $113.75 billion, a P/E ratio of 17.58 and a beta of 1.50. AbbVie also saw unusually large options trading activity on Monday. Stock traders bought 278 put options on the stock. This is an increase of 121% compared to the average daily volume of 126 put options.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s payout ratio is presently 62.90%.

In related news, Chairman Richard A. Gonzalez sold 87,899 shares of AbbVie stock in a transaction on Friday, August 4th. The shares were sold at an average price of $71.02, for a total value of $6,242,586.98. Following the transaction, the chairman now owns 342,353 shares in the company, valued at approximately $24,313,910.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO William J. Chase sold 38,300 shares of AbbVie stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the completion of the transaction, the chief financial officer now owns 209,043 shares in the company, valued at approximately $13,660,960.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 600,026 shares of company stock worth $41,852,724. 0.23% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Atwood & Palmer Inc. boosted its position in shares of AbbVie by 120.9% in the second quarter. Atwood & Palmer Inc. now owns 4,750 shares of the company’s stock worth $344,000 after buying an additional 2,600 shares during the last quarter. RBO & Co. LLC boosted its position in shares of AbbVie by 0.9% in the second quarter. RBO & Co. LLC now owns 109,848 shares of the company’s stock worth $7,965,000 after buying an additional 967 shares during the last quarter. Good Life Advisors LLC acquired a new position in shares of AbbVie during the second quarter worth approximately $247,000. Gratus Capital LLC acquired a new position in shares of AbbVie during the second quarter worth approximately $5,490,000. Finally, Sullivan Bruyette Speros & Blaney LLC boosted its position in shares of AbbVie by 2.9% in the second quarter. Sullivan Bruyette Speros & Blaney LLC now owns 15,051 shares of the company’s stock worth $1,091,000 after buying an additional 424 shares during the last quarter. Institutional investors own 67.89% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.